Brief: HBM Holdings Enters Strategic Collaboration With China National Pharmaceutical Group On Biologics Research And Development
27/07/2026 11:29
BRIEF-HBM Holdings Enters Strategic Collaboration With China National Pharmaceutical Group On Biologics Research And Development July 27 (Reuters) - Hbm Holdings Ltd 2142.HK:
ENTERS STRATEGIC COLLABORATION WITH CHINA NATIONAL PHARMACEUTICAL GROUP ON BIOLOGICS RESEARCH AND DEVELOPMENT
CO AND CHINA NATIONAL PHARMACEUTICAL GROUP TO COLLABORATE ACROSS FULL BIOLOGICS RESEARCH AND DEVELOPMENT LIFECYCLE, WITH FOCUS ON ONCOLOGY, OTHERS
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study